Tuesday, June 27, 2017

Studies Show Obamacare Improves Breast Cancer Prognosis, Cutting Medicaid Puts Women at Risk

Two separate analyses demonstrate that women with access to mammograms 
and other breast cancer screenings are diagnosed at earlier, more treatable, 
and less costly stages.

More women were diagnosed with early stage breast cancer after the Affordable Care Act took effect, according to a study published this month in the journal Cancer Epidemiology.  Equally important, there was a decrease in later stage, and more serious, cancers.

Late-stage breast cancer is more costly to treat and is more likely to be fatal than early-stage cancer.

Increases in early diagnoses were higher among African American and Latina breast cancer patients. 
In the past, the cost of mammograms has prevented many Latinas and African Americans to receive mammograms overall or at recommended intervals.

The Affordable Care Act eliminated copayments and other out-of-pocket costs for 45 preventive care services, including mammograms, making them more affordable and leading to the potential for earlier diagnoses, researchers say. Diagnosing breast cancer when it is still in Stage 1 could improve the prognosis for thousands of women and reduce the need for expensive and invasive treatments such as chemotherapy, wrote lead author Abigail Silva, PhD, MPH, of Loyola University Chicago Stritch School of Medicine.
 

The study included 470,465 breast cancer patients between the ages of 50 and 74 who were covered by private insurance or Medicare and were newly diagnosed with breast cancer. Researchers examined two time periods: 2007-2009 (before the Affordable Care Act took effect) and 2011-2013 (after the act took effect). They used data from the National Cancer Database, which includes approximately 70 percent of all newly diagnosed cancers in the United States from about 1,500 hospitals.
 

Overall, the number of breast cancers that were diagnosed at Stage 1 increased 3.6 percent, from 54.4 to 58.0 percent. There was a corresponding decrease in Stage 2 and Stage 3 diagnoses, while the proportion of Stage 4 cancers did not change.

The diagnosis of Stage 1 breast cancer increased by 3.2 percentage points among whites, 4.0 percentage points among African Americans and 4.1 percentage points among Latinas. 


Historically, more white women are diagnosed with Stage 1 breast cancer, while African Americans and Latinas are diagnosed at a higher stage. This disparity decreased following the Affordable Care Act, as minorities saw improvements in Stage 1 diagnoses.
 

This is especially significant for triple-negative breast cancer, which has been shown to be more prevalent and aggressive among African Americans.

Cutting Medicaid Puts Women At Risk
Tennessee women with breast cancer were more likely to be diagnosed at later, more dangerous, stages after a substantial rollback of Medicaid coverage for adults in the state, with the biggest effects being among women in low-income areas, according to an analysis published in the journal Cancer.

Researchers analyzed Tennessee Cancer Registry data from 2002 to 2008 and compared women 
diagnosed with breast cancer who lived in low-income zip codes with a similar group of women who 
lived in high-income zip codes, before and after Tennessee’s Medicaid restrictions. They found that 
women were not only diagnosed at later stages but also experienced more delays in treatment after 
the restrictions were imposed. Low-income women had a 3.3 percent increase in late-stage diagnosis 
compared to those with higher incomes.

Tennessee restricted Medicaid enrollment in 2005

The findings suggest that women did not get screenings or other essential primary care that may 
have led to an earlier diagnosis, according to team leader Wafa Tarazi, PhD, of Virginia 
Commonwealth University. The reason: lack of affordable care.


“Medicaid rollbacks may contribute to widening disparities in health outcomes between low-income women and their wealthier counterparts,” said team leaders Lindsay Sabik, PhD, of the University of Pittsburgh, another team leader.

Wednesday, June 14, 2017

Immunotherapy Trials Encouraging for Metastatic TNBC

The first triple negative breast cancer immunotherapy trial to date has yielded some hopeful results for metastatic TNBC, according to results presented at the 2017 American Society of Clinical Oncology Annual Meeting.
The checkpoint-blocking drug Keytruda shrank pre-treated tumors by more than 30 percent in 5 percent and stabilized disease in 21 percent of women in the group. All patients who saw their tumors shrink lived for at least another year. In comparison, the patients who did not experience tumor regression had lower survival rates. (Remember: This is metastatic TNBC, or stage 4, not earlier, or more treatable, forms, such as stages 1-3.)
The trial included two groups of patients with metastatic TNBC. The first consisted of 170 patients who had received earlier chemotherapy. The second group was previously untreated and had tumors expressing the checkpoint molecule PD-L1.
Both groups tolerated the treatment well, with 12 percent of patients in the first group, and 8 percent in the second group reporting side effects such as fatigue and nausea. Four percent of patients in the first group, but none in the second, stopped the treatment because of these effects.

Monday, April 24, 2017

Radiation Recall? A Search for What Caused My Chest Inflammation After A Mastectomy

More than ten years after I had radiation on my breast, I developed a skin inflammation on the radiated site. It came on suddenly, a series of angry red veins branching across my chest where my left breast had been, with occasional darker, pooled spots, all in a rectangular shape matching the area where I had been radiated. My skin was smooth, with no bumps or lumps.

It was November 2016, a year and a half after my second bout of triple-negative breast cancer. My cancer story in a nutshell: I have had TNBC twice: once in 2006 and once in 2015. The second was not a recurrence, but a second primary cancer. For the first cancer, I had a lumpectomy, chemo, and radiation. The second time, with a tumor less than half a centimeter, I had a double mastectomy without reconstruction.

I had absolutely no problems with radiation burns while undergoing my original treatment, nor in the intervening ten years, although I do think it highly possible radiation was one cause of my second cancer.

The mastectomy, though, did not go all that smoothly. I developed seromas for months afterward, the last one being essentially a blood-filled bruise. The surgeon drained it and, within days, it had healed, but for a few days, the skin looked a little like the inflammation I was now seeing. At that time, my surgeon said the skin was weakened by the long-ago radiation and became even more damaged by the more recent surgery.

I went for a year after that last seroma with what might be considered normal healing after a mastectomy: some arm and incision pain, but nothing unusual. Now something was up. But what?

Radiation Recall

After checking online, I self-diagnosed radiation recall, which can occur years after radiation. Most cases are drug-related, caused when patients are given cancer-fighting drugs such as anthracyclines like adriamycin, after radiation. I had been given adriamycin, but that was ten years ago. Why would I now be having a reaction? It had to be something else. Chat rooms were full of discussions of women with radiation recall, with causes all over the board: scented lotions, wool, new prescriptions or over-the-counter drugs. Treatments were equally varied: antihistamines, steroid creams, and anti-inflammatory drugs such as ibuprofen.

Some mentioned that chest inflammation could be lymphedema of the trunk, which made a little sense, as my case was accompanied by pain in my upper arm. But mine was milder than those I saw online. I had none of the swelling that was indicative of lymphedema. 

The basic message from my research, though, was encouraging: Radiation recall is not usually a sign of a new cancer and is most likely a skin issue, some form of dermatitis.

My inflammation looked far, far better than photos I saw online, which showed chests that were completely red, often scaly. Mine looked modest in comparison. The closest was this one, which they call photo recall. Most other images made me thank my lucky stars.

As I was trying to figure this all out, a friend who is 11 years past her TNBC diagnosis messaged me and said that she has been diagnosed with radiation fibrosis. So I researched that, but I had none of the scarring that is characteristic of that syndrome. Still, it is a late effect for some breast cancer patients and seems worse for head, neck and throat cancer patients. Interestingly, a University of Iowa clinical trial recommended Vitamin E for radiation fibrosis, but vitamin E turned my skin red every time. That was one of the few direct effects I could see, and it ran contrary to much of what I read in general about soothing breasts to help them heal after surgery and to reduce radiation effects.

At the same time my chest got inflamed, I had throat phlegm that would not clear up and I remembered my friend Marilyn, who thought she had bad allergies but ended up having a recurrence of TNBC on her chest wall. I decided that was what was happening to me—the phlegm, as in Marilyn’s case, was an indication of a tumor, and the skin inflammation was just verification. Clearly, I was dying, because that is the conclusion we reach in these situations, right?  But I went to my primary care doctor for a professional assessment, just to be sure.

By the day of my appointment, the inflammation had almost disappeared—only a couple inflamed veins remained. The doc had to use a flashlight to see the reddened veins and was, not surprisingly, skeptical of my worries. As for the phlegm, she looked down my throat with a scope and felt my lymph nodes. Nothing again.  

“Could this be stress?” I asked her. This happened right after the election and I am a Democrat, so stress is my best buddy these days. “If you want it to be,” she answered. I mentally put that on my list of Obnoxious Things Doctors Have Said To Me.

But she told me that if that inflammation got worse or if the throat didn't get better in two weeks, to come back.

The next day, the skin got redder, but rather than heading back to the doctor, I began a diary of possible causes. The phlegm soon disappeared, so my focus returned to my skin, to this being a dermatological issue.

Searching For a Cause

I had worn a wool sweater the day the inflammation came on, with a nylon camisole underneath. That seemed like an obvious cause, so I stopped wearing any synthetics and used only cotton. I have worse only cotton in the five months since then. No real change, although the inflammation gets better for a bit, then worse again.

I use organic, unscented laundry soap, but I changed brands. No help.

I tried steroid creams and ibuprofen but noted no obvious cause and effect. I upped my dose of antihistamines. Nothing, except I got pretty sleepy.

I began to suspect some of the supplements I was taking, including a new multivitamin I began using the day after all this happened. Why it would have caused anything the day before I started it makes no sense, but I stopped it anyway. I even moderated my yoga, as it often hurts my affected arm and I thought maybe that could be related to the rash. So I cut out anything that put pressure on the arm. 

Again, the inflammation got better, then it got worse, and I could not determine any common factors. I concluded that it must be a mix of causes, some sort of perfect biological storm.

Then, I got a series of bumps along my incision. One was about a quarter of an inch in diameter. Again, I was clearly dying. If cancer recurs, it often comes as a rash at the incision site. This time, I made an appointment with my surgeon. But, by the time that appointment came, the bumps had shrunk and the inflammation as a whole had greatly reduced.

He came in somber-faced and I tried to tell him I was sure I had overreacted, but he wanted to go over my entire medical history before he looked at the rash. I was there with a recurrence, he thought, and that was not good news. Once he saw my chest, though, he smiled and said the bumps were clearly not tumors. Nevertheless, he wanted me to get a chest x-ray. More radiation? I asked. Low doses, he said. He wanted to make sure this had not spread to my lungs. Reluctantly, I agreed, acknowledging that by deciding to go to the surgeon in the first place, I at least subconsciously wanted the kind of answer that additional tests would give.

He called me the next day—my lungs were clear, except for the signs of COPD, which I knew I had. No tumors.

That day, the skin bloomed a bright purple again. A reaction to the x-ray? Who knows, but it’s hard to discount that possibility. But it healed a bit, then bloomed bright and angry again. So I went back to my diary, back to trying to figure out what was going on with my blasted chest.

I began to suspect the tonic water in my nightly gin and tonic, a drink I know I am better off without, so I cut it out and replaced it with healthier black cherry juice without gin. The rash again got better, then worse. There just seemed no pattern.

Three weeks after seeing the surgeon, I had my yearly appointment with the dermatologist. He looked at the inflammation, said it was probably harmless irritation, but took a biopsy nevertheless. Again, I was annoyed at the extra testing, but equally curious to see what it would show. The result: my skin was inflamed, but there were no signs of cancer. The pathologists suggested the inflammation was caused by a new drug or by contact with an allergen of some sort.

So, three doctors, an x-ray, and a biopsy later, I was right back where I was with my original Google search. This was likely caused by something I had injected or exposed my skin to. Except for one thing: after the biopsy, the rash cleared up almost entirely. More than ever before. Now, three weeks later, it is still mostly clear—just a few faint lines remain, but those might always be there. Gone are the red veins, the purple pools.

Why?

A Partial Answer

After the biopsy, I was advised not to shower that area—I had to gently clean it with a cloth. No hot water flowing over it. So, my dermatologist might have accidentally solved at least part of my mystery. I had been taking long showers to alleviate my stress after the election and, if all that hot water wasn't the cause, it was certainly exacerbating my inflammation. I’ve cut down on my showers, which is an environmentally kind thing to do in the first place. And my chest now looks almost normal, in the context of chests that have been radiated, deflated, and deformed. 

Eventually, perhaps, I will reintroduce some of the elements—my multivitamins, yoga arm exercises, tonic water—bit by bit and see what happens. Maybe I will eventually figure out what caused this, and maybe eventually my skin will be completely clear and this will all be a weird memory. What is obvious is that docs have no idea.

And right now, the only dark marks on my chest are the two spots where the doc took the biopsy. But even they are healing nicely.

Mystery unsolved, except there are no signs of cancer. And that, as always, is a good thing.


Wednesday, April 19, 2017

Cancer Professionals and Patients Anxious About Changes in Obamacare


Oncology professionals are concerned about the ability of their patients to access cancer screening and treatment under the American Health Care Act proposed by House Speaker Paul Ryan, according to a survey conducted in March at the National Comprehensive Cancer Network’s  Annual Conference.

A majority of those surveyed believed that anticipated changes to the Patient Protection and Affordable Care Act (Obamacare) would have a negative impact on their practices and on cancer research. More than 70 percent noted that patients have voiced concern about the anticipated repeal and replacement of Obamacare, nearly two-thirds of whom have demonstrated increased levels of distress.

The survey was conducted during the period of congressional debate over the American Health Care Act (AHCA), which was withdrawn the afternoon of March 24 when it became clear there were not enough votes to pass the legislation. Responding to the survey were 76 oncology professionals, including physicians, academic and community; nurses; physician assistants; pharmacists; industry professionals; payers and patient advocates. Republicans in the House continue to discuss ways to repeal or change the law.

“The American Health Care Act is tabled and the ACA remains in place, but concerns about access to cancer screening, care, and research funding remain. Today, patients are in limbo, not knowing what action the federal and state governments will take,” said Robert W. Carlson, MD, Chief Executive Officer of NCCN. “NCCN agrees there are ways to improve the current health care system for Americans with cancer, the clinical professionals who care for them, and payers. However, we are concerned for Americans with cancer that affordability, coverage of products and services in cancer treatment, and overall access will be impeded by allowing health insurers to set their own rates, or by providing states the ability to experiment with Medicaid coverage, without appropriate patient protections.”

The NCCN survey found:

Fifty-five percent of respondents reported that the anticipated large-scale changes to federal health care policy would likely have a negative impact on their practice, research programs or patient outcomes. Eleven percent anticipated a positive impact, and 34 percent anticipated a neutral, or mixed impact.
  When asked to select from a list of outcomes they anticipated would occur with changes to health care policy, those who anticipated a negative impact (55%) indicated:                         
   Fewer patients will have access to health insurance (71%)  High deductibles will limit patient access to care (69%)  Cancer screening rates will decline due to higher co-pays and deductibles (63%)  Patients’ pre-existing conditions could be excluded from coverage (57%)  Federal funding for cancer research will decline (56%)  There will be less support for mental health services (50%)
Those who expected a positive impact (11%) indicated:
   With increased competition for insurers operating across state lines, health insurance premiums and co-pays will go down for more patients, leading to improved access to care (50%)  Allowing medications to be imported will create more competition and reduced drug prices (50%)  Patient health savings accounts will lead to increased price transparency for medical procedures and medications, causing health care costs to drop (38%)
  When asked, “What kind of impact do you believe changes in federal health care policy will have on your patients’ ability to afford cancer care?” 66 percent of respondents said the impact would be negative; nine percent said positive; and 25 percent said the impact would be neutral.

   And, to the question, “To your knowledge, are your patients affected by health insurance policy and the possible repeal and replacement of the Affordable Care Act?” respondents answered:   
 Yes, patients have expressed concern and demonstrated greater levels of distress (50%)  Yes, patients have expressed concern but no evidence of health impact (21%)  No, I have not seen any effects (29%) 
“President Trump included three key elements in his approach to health coverage reform: repairing necessary aspects of the ACA, ensuring greater access, and lowering the total cost of care,” Dr. Carlson said. “We are ready to share our Network’s expertise with lawmakers to deliver a value-based health policy to ensure that all Americans with cancer have access to high-quality, effective, and efficient cancer care.”

Read Dr. Carlson’s March 21, 2017 letter to Congress outlining NCCN’s concerns about the health policy proposal and patient access to care here.

Information from a news release provided by the National Comprehensive Cancer Network.